UPDATE
: Monday, September 7, 2020
Home
Login
Mobile Version
All
Hospital
Pharma
Bio
Korea‘s Bio Industry
Device/ICT
Policy
People
Life science
Special
Innovation for Survival
Korea’s medical culture series
Korea’s New Candidate Drug Watch List
Special Series in Celebration of KBR's 1st Anniversary
Interview with foreign envoys
Special Series in Celebration of KBR’s 2nd Anniversary
Interview with global pharma
Special Series in Celebration of KBR’s 3rd Anniversary
Special Series in Celebration of KBR’s 4th Anniversary
ASCO 2020 Highlights
Opinion
Reporter’s Notebook
Search
트위터
페이스북
RSS
상단여백
제목보기
제목보기
제목+내용
Celltrion unveils clinical results of Remsima SC in treating IBD
by Lee Han-soo
2019-10-22 17:00
Biogen, Samsung Bioepis to present biosimilar data at EU conference
by Lee Han-soo
2019-10-22 11:31
Medytox exported ₩3.3 billion worth of unqualified BTX
by Jeong Sae-im
2019-10-18 16:02
State organs squandered ₩8.2 billion; failed to spot Invossa problem
by Kwak Sung-sun
2019-10-16 15:06
[Exclusive] Samsung admits it failed to develop Rituxan biosimilar
by Jeong Sae-im
2019-10-16 14:16
라인
Kolon Life Science shares surge after TissueGene’s survival
by Jeong Sae-im
2019-10-14 18:01
HLB merges with Elevar to own rivoceranib rights
by Jeong Sae-im
2019-10-14 14:43
Samsung Bioepis to present data of Etanercept biosimilar in Europe
by Lee Han-soo
2019-10-10 11:31
‘Kosdaq firms listed for exceptional tech need special monitoring’
by Jeong Sae-im
2019-10-07 15:51
SK Plasma launches human immunoglobulin in Brazil
by Lee Han-soo
2019-10-07 11:23
라인
‘New law to support advanced biopharmaceuticals, ensure safety’
by Lee Hye-seon
2019-10-04 15:18
Samsung execs pass buck to biotech subsidiaries for destroying evidence
by Jeong Sae-im
2019-10-04 11:42
Samsung Bioepis releases P3 results of Bevacizumab biosimilar in EU
by Lee Han-soo
2019-09-27 11:37
‘Samsung BioLogics destroyed evidence to hide accounting fraud for months’
by Jeong Sae-im
2019-09-26 15:24
Celltrion to start marketing Herzuma in Middle East
by Lee Han-soo
2019-09-26 15:02
라인
Helixmith blames hospital for absurd drug mix-up
by Jeong Sae-im
2019-09-25 13:42
Court rejects Kolon’s appeal over Invossa license revocation
by Jeong Sae-im
2019-09-25 11:18
FDA recommends Kolon to remanufacture Invossa’s second fluid
by Jeong Sae-im
2019-09-23 15:32
Dong-A ST's Aranesp biosimilar gets nod in Japan
by Lee Han-soo
2019-09-23 15:31
Biotech startups seek IPO via ‘growth potential exception’ policy
by Jeong Sae-im
2019-09-17 11:26
-
1
2
3
4
5
6
7
8
9
10
다음
-
176 civic groups furious over government-doctors deal
Amgen Korea wins new indication for acute lymphoblastic leukemia drug
UBcare wins patent for tech to monitor suspected infectious diseases
SCM Lifescience punished for delaying adverse reaction report
176 civic groups furious over government-doctors deal
Amgen Korea wins new indication for acute lymphoblastic leukemia drug
UBcare wins patent for tech to monitor suspected infectious diseases
SCM Lifescience punished for delaying adverse reaction report
여백
Most viewed
1
‘Cyramza helped improve gastric cancer treatment in Korea’
2
‘Reduced-dose prasugrel effective for ACS patients undergoing PCI’
3
Amgen Korea wins new indication for acute lymphoblastic leukemia drug
4
SNUBH develops AI model predicting patients at risk of cerebral aneurysm
5
Novavax releases encouraging phase-1 results on Covid-19 vaccine candidate
6
LG Chem, SK Bioscience end sales partnership with Daewoong
7
UBcare wins patent for tech to monitor suspected infectious diseases
8
176 civic groups furious over government-doctors deal
9
Recovered Covid-19 patients suffer from aftereffects – for long
10
Regulator OKs JW Pharma's rheumarthritis drug for treating giant cell arteries
여백
Opinion
[Column] Correct diagnosis leads to proper treatment
[Column] How ongoing doctors’ strike is different from 20 years ago
A Korean-American Doctor asks: Is Korea truly in 2020?
여백
Back to Top